ASMB — Assembly Biosciences Share News
0.000.00%
Last trade - 00:00- $403.95m
- $83.59m
- $72.30m
Brief: Gilead And Assembly Biosciences In Partnership To Develop Next-Generation Therapeutics For Viral Diseases
Brief: Assembly Biosciences Nominates Development Candidate Abi-6250, An Orally Bioavailable HDV Entry Inhibitor
Brief: Assembly Biosciences On Sept 27 Got Letter From Nasdaq That Co Was Not In Compliance With Nasdaq Listing Rule
Assembly Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Assembly Biosciences Q2 EPS USD -0.32
Assembly Biosciences Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Assembly Biosciences Announces Additional Promising Data From Phase 1A Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate Abi-4334
Brief: Assembly Biosciences Files For Mixed Shelf Of Up To $150 Mln - SEC Filing
Brief: Assembly Biosciences Posts FY Loss Per Share Of $1.92
Assembly Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Assembly Biosciences Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Assembly Biosciences Nominates First Herpesvirus Development Candidate Abi-5366
Brief: Assembly Biosciences Announces Promising Interim Results From Two Clinical Trials Evaluating Next-Generation Core Inhibitor Candidates
Assembly Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Assembly Biosciences Reports Third Quarter 2022 Financial Results
Brief: Assembly Biosciences Presents New Data At AASLD The Liver Meeting Highlighting Breadth Of Virology Portfolio And Potential Of Next-Generation Core Inhibitors In HBV
Assembly Biosciences Inc expected to post a loss of 47 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Assembly Biosciences, Aveo Oncology, SVB Financial Group
Brief: Assembly Bio Announces Retirement Of John Mchutchison As CEO